About Synairgen Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. Synairgen is currently fully focused on progressing its inhaled interferon beta1a broad spectrum antiviral drug as an effective treatment for people suffering with COVID-19 infection. Synairgen s differentiating human biology BioBank platform and world-renowned international academic KOL network has broader applicability for lung viral defence in other respiratory disorders including asthma and COPD. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com COVID-19 COVID-19, caused by the SARS-CoV-2 virus, is a global threat and there is an urgent need to assess new treatments to prevent and effectively treat the severe lower respiratory tract illness that can occur with this disease. Older people
About Synairgen Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. Synairgen is currently fully focused on progressing its inhaled interferon beta broad spectrum antiviral drug as an effective treatment for people suffering with COVID-19 infection. Synairgen s differentiating human biology BioBank platform and world-renowned international academic KOL network has broader applicability for lung viral defence in other respiratory disorders including asthma and COPD. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com SNG001 (inhaled Interferon beta) applicability to COVID-19
12 Jan 2021 / 04:56 H.
By Nancy Lapid
Jan 11 (Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
Half a year later, COVID-19 patients still have symptoms
Most patients hospitalized with COVID-19 have at least one symptom six months after falling ill, according to findings from a study in Wuhan, China, where the novel coronavirus first emerged in late 2019. Doctors there tracked 1,733 patients who were diagnosed and hospitalized between January, 2020 and May. Six months later, 76% had at least one symptom including fatigue or muscle weakness (seen in 63%), sleep difficulties and anxiety or depression. Most of those who had been severely ill had ongoing lung problems and chest abnormalities that could indicate organ damage, while 13% of patients whose kidneys functioned normally in the hospital went on to develop kidney problems later, res